2 q14 slides final

DuPont Second Quarter 2014 Earnings Conference Call July 22, 2014

2

Regulation G The attached charts include company information that does not conform to generally accepted accounting principles (GAAP). Management believes that an analysis of this data is meaningful to investors because it provides insight with respect to ongoing operating results of the company and allows investors to better evaluate the financial results of the company. These measures should not be viewed as an alternative to GAAP measures of performance. Furthermore, these measures may not be consistent with similar measures provided by other companies. This data should be read in conjunction with previously published company reports on Forms 10-K, 10-Q, and 8-K. These reports, along with reconciliations of non-GAAP measures to GAAP are available on the Investor Center of www.dupont.com under Filings and Reports – Reconciliations and Other Data. Reconciliations of non-GAAP measures to GAAP are also included with this presentation.

Forward Looking Statements During the course of this presentation we may make forward-looking statements or provide forward-looking information. All statements that address expectations or projections about the future are forward-looking statements. Some of these statements include words such as “plans,” “expects,” “will,” “anticipates,” "believes," “intends,” and “estimates.” Although they reflect our current expectations, these statements are not guarantees of future performance, but involve a number of risks, uncertainties, and assumptions. Some of which include: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; global economic and capital markets conditions; litigation and environmental matters; changes in laws and regulations or political conditions; business or supply disruptions; ability to protect and enforce the company’s intellectual property rights successful integration of acquired business and separation of underperforming or non-strategic assets; and successful completion of the proposed spinoff of the Performance Chemicals segment including ability to fully realize the expected benefits of the proposed spinoff. The company does not undertake to update any forward-looking statements as a result of future developments or new information.

Developing Markets Total developing markets is comprised of Developing Asia, Developing Europe, Middle East & Africa, and Latin America. A detailed list of all developing countries is available on the Earnings News Release link on the Investor Center website at www.dupont.com.

2

http://www.dupont.com/

3

$ in millions, except EPS 2Q 2014 Financial Highlights*

* Amounts reflect continuing operations ** See appendix for reconciliations of Non-GAAP Measures

2Q14 vs. 2Q13 YTD14 vs. ‘13 EPS* Operating earnings** $1.17 (9%) $2.75 (3%) GAAP earnings $1.15 5% $2.70 5%

Segment Operating Earnings** $1,770 (5%) $4,018 (3%)

2Q14 vs. 2Q13 YTD14 vs. ‘13

Consolidated Net Sales* $9,706 (1%) $19,834 (2%)

Volume - (1%)

Local Prices - -

Currency Impact - -

Portfolio (1%) (1%)

4

2Q 2014 Segment Operating Earnings* Variance

Key Takeaways

Nutrition & Health earnings up 72% on broad based volume gains, operating margins +400bps

Safety & Protection earnings up 22% on higher margins and improved volumes Industrial Biosciences earnings up 37% on mix enrichment, higher margins, improved

volumes Performance Materials volume growth in auto product lines offset by scheduled shut down

in Orange, TX facility Agriculture earnings declined due to lower corn seed volumes impacted by reductions in

corn planted area and higher seed inventory write-downs * See appendix for details of significant items and reconciliation of Non-GAAP Measures

$1,857 Segment

Operating Earnings*

($105) ($17) $44

($27)

($29) ($6) $37 $16

$1,770 Segment

Operating Earnings*

2Q13 N&H S&P IB E&C Perf Mtls Perf Chem Ag Other 2Q14

5

Global Sales – Regional Highlights

2Q 2014 Sales YOY % CHG 2Q 2014 Sales by Region

U.S. & Canada 47%

Developing EMEA

6%

Developed EMEA 16%

Developing Asia 13%

Developed Asia 9%

Latin America 9%

Region %

Worldwide -1%

U.S. & Canada -3%

Developed EMEA +5%

Developed Asia -5%

Developing Markets -1%

Developing Asia +3%

Developing EMEA -5%

Latin America -4%

6

2Q 2014 Operating EPS* Variance

* See appendix for details of significant items and reconciliation of Non-GAAP Measures

Key Takeaways

Net after-tax exchange losses (EGL) reflect increased currency rate volatility, principally in emerging markets, coupled with higher costs associated with the Company’s currency hedging program and currency devaluation in Ukraine

The base tax rate was 23.3%* compared to 24.1%* in the prior year; anticipate full year base tax rate of about 22%

$1.28 Operating*

EPS

($0.07) $0.01 $0.01 ($0.08) $0.02

$1.17 Operating*

EPS

2Q 2013 Corporate &Interest Exp

Taxes Lower shares Segmentresults

Exchange Gains(Losses)

2Q 2014

7

Balance Sheet and Cash June 30, 2014

Free Cash Flow • ~$.6B improvement YOY • Lower tax payments associated with the

2013 sale of Performance Coatings

Balance Sheet • $7.5B net debt** • $1.7B maturing debt retired YTD • $1.1B in share repurchases – about 17

million shares

Use of Cash for remainder of 2014 • Expect $0.9B share repurchase • Dividends • CapEx spend est. $1.9B FY 2014 • Continued growth investments; in line with

strategy

* Free Cash Flow is cash used by operating activities of ($2,071MM) and ($2,631MM) less purchases of plant, property and equipment of $781MM and $757MM for the six months ended June 30, 2014 and 2013, respectively.

** See appendix for reconciliation of Non-GAAP measures.

Free Cash Flow*

-3.0

-2.0

-1.0

0.0YTD 13 YTD 14

$ B

illio

ns

0

4

8

12

16

Dec-12 Mar-13 Jun-13 Sep-13 Dec-13 Mar-14 Jun-14

$ B

illio

ns

Gross Debt Cash Net Debt**

Cash and Debt

8

Other Financial Highlights

• Redesign initiative with cost reduction of at least $1B launched in the quarter

• On track to complete Performance Chemicals separation

in mid 2015

• Announced 4% ($.02/share) increase in the third quarter dividend on common shares. Third dividend increase in 27 months.

• 2014 Full Year Operating EPS* outlook reaffirmed $4.00 - $4.10 per share

* See appendix for details of significant items and reconciliation of Non-GAAP Measures

9

Nutrition & Health

0.0

0.2

0.4

0.6

0.8

1.0

2Q12 2Q13 2Q14

$ in

Bill

ions

2Q Sales *

2Q Comments

Sales were 7% higher primarily due to broad based volume growth aided by improved mix

Operating earnings of $105 million increased 72% from higher sales, lower raw material costs, productivity gains and absence of one-time costs in prior year

Operating margin improved by over 400 basis points

2Q Operating Earnings **

2Q12 2Q13 2Q14 0%

3%

6%

9%

12%

0

20

40

60

80

100

120M

argi

n

$ in

Mill

ions

3Q Outlook

Expect modest sales growth from continued broad based volume gains

Operating earnings are expected to be significantly higher due to higher sales, mix enrichment and productivity, partially offset by growth investments

Operating margins are expected to continue to show year over year improvement

* Segment sales include transfers. ** See appendix for reconciliation of non-GAAP measures.

10

Industrial Biosciences

2Q12 2Q13 2Q14 0%

4%

8%

12%

16%

20%

0

10

20

30

40

50

60

Mar

gin

$ in

Mill

ions


2Q Sales * 2Q Comments

Sales up 4% on higher prices due to mix enrichment, continued strong demand for enzymes used in ethanol production

Earnings up 37% on mix enrichment, higher margins and improved volumes

Bioactive sales up mid-single digits on strong enzyme demand in animal nutrition and food applications

Operating earnings of $59 million, operating margin up 450 bps.

3Q Outlook

3Q sales up modestly on continued enzyme demand for ethanol production

Enzyme demand in animal nutrition, detergents, and food enzyme markets supporting ongoing sales growth

3Q operating earnings up substantially on higher volumes and improved operating margins

0.0

0.1

0.2

0.3

0.4

2Q12 2Q13 2Q14

$ in

Bill

ions


11

Safety & Protection Protection Technologies (DPT), Building Innovations (BI), Sustainable Solutions (DSS)

0.0

0.2

0.4

0.6

0.8

1.0

1.2

2Q12 2Q13 2Q14

$ in

Bill

ions

3Q Outlook

Sales up modestly reflecting continuing demand growth in global industrial markets

Demand improvement led by Asia and North America

3Q operating earnings up about 20% driven by higher operating margins and sustained operational productivity

0%

5%

10%

15%

20%

25%

0

50

100

150

200

250

2Q12 2Q13 2Q14

Mar

gin

$ in

Mill

ions

2Q Sales *


2Q Comments

Sales up 1% due to higher volumes from industrial markets

Improved sales for Nomex® thermal resistant and Kevlar® high strength materials in industrial markets partially offset by lower sales from Clean Technologies offerings

Operating margins up over 300 basis points Operating earnings up 22% due to higher margins,

improved volume and sustained productivity gains

* Segment sales include transfers. ** See schedule C in the earnings news release for reconciliation of

non-GAAP measures. * Segment sales include transfers. ** See appendix for reconciliation of non-GAAP measures.

12

Electronics & Communications

0%

4%

8%

12%

16%

0

25

50

75

100

125

2Q12 2Q13 2Q14

Mar

gin

$ in

Mill

ions

0.0

0.2

0.4

0.6

0.8

1.0

2Q12 2Q13 2Q14

$ in

Bill

ions

2Q Sales *


3Q Outlook

Continue to expect global photovoltaic module installations to be up for the year with mid-teens growth rates

Expect strong 2H in PV driven by installations in China and good demand in consumer electronics markets

3Q sales are expected to be slightly higher with operating earnings slightly lower due to a decrease in other income

2Q Comments

Sales were essentially flat excluding the impact of lower metals price pass through

Volume growth in most product lines, led by gains in consumer electronics, was offset by lower price due to metals, product mix and competitive pressures

Operating earnings declined $6 million as volume growth and productivity gains were more than offset by the absence of $20 million of OLED licensing income realized during the second quarter of 2013

Excluding the impact of last year’s licensing income, operating earnings increased 19%


13

Performance Materials*** Performance Polymers (DPP), Packaging & Industrial Polymers (P&IP)

0%

5%

10%

15%

20%

25%

0

75

150

225

300

375

2Q12 2Q13 2Q14

$ in

Mill

ions

0.0

0.4

0.8

1.2

1.6

2.0

2Q12 2Q13 2Q14

$ in

Bill

ions

2Q Sales *


2Q Comments

Sales down 2% due to lower volumes resulting from the scheduled ethylene outage and portfolio impact of the GLS/Vinyls sale

Demand for Performance Polymers up mid-single digits due to strengthening automotive market

Demand environment in consumer, construction, and food packaging markets remains stable

Operating earnings down 9% as higher sales in automotive were more than offset by reduced supply of ethylene and the portfolio impact of the GLS/Vinyls sale

Mar

gin

* Segment sales include transfers. ** See appendix for reconciliation of non-GAAP measures. *** Prior periods reflect reclassification of Viton® fluoroelastomers from Performance Materials to Performance Chemicals

3Q Outlook

3Q sales essentially flat due to the GLS/Vinyls sale

Consumer, construction, and food packaging volumes forecasted to remain stable

Automotive volumes anticipated to remain strong led by China and Europe

3Q operating earnings up modestly versus prior year which included a $30 million benefit related to a JV equity position

14

Performance Chemicals*** Titanium Technologies (DTT), Chemicals & Fluoroproducts (DC&F)

2Q Sales *


0.0

0.5

1.0

1.5

2.0

2Q12 2Q13 2Q14

$ in

Bill

ions

0%

6%

12%

18%

24%

30%

36%

0

100

200

300

400

500

600

700

2Q12 2Q13 2Q14

Mar

gin

$ in

Mill

ions

3Q Outlook

3Q sales essentially flat

Industrial Chemicals, Fluoropolymers and Opteon® yf refrigerant volumes forecasted higher

Ti02 industry environment remains stable, moderately lower ore costs anticipated

3Q operating earnings up moderately on improved volumes and margins

* Segment sales include transfers. ** See appendix for reconciliation of non-GAAP measures *** Prior periods reflect reclassification of Viton® fluoroelastomers from Performance Materials to Performance Chemicals

2Q Comments

Sales of $1.7 billion were down 8% due primarily to a portfolio change and lower prices

Lower refrigerant prices, principally R22 and 134a, impacted operating earnings

Ti02 volumes were up slightly and prices were down about 3% from the prior year

Operating earnings down 6% primarily due to lower segment prices

15

Agriculture Pioneer, Crop Protection

0.0

1.0

2.0

3.0

4.0

5.0

2Q12 2Q13 2Q14

$ in

Bill

ions


2Q Sales *

2Q12 2Q13 2Q14 0%

5%

10%

15%

20%

25%

30%

0

250

500

750

1,000

1,250

1,500

Mar

gin

$ in

Mill

ions

2H Outlook

2H sales expected to be modestly higher with operating earnings substantially higher

Growth in insecticide volumes aided by new product launches of Cyazypyr® insecticide and Dermacor™ seed treatment in Brazil

Lower Brazil summer corn seed volumes and price

4Q seed shipments for the 2015 Brazil Safrinha and northern hemisphere seasons similar to the prior year

Expect a similar 3Q loss as the prior year followed by a stronger 4Q

2Q and 1H Comments

Supply driven impacts on commodity prices led to reductions in corn planted area in the North America and Brazil Safrinha seasons

2Q sales flat as higher seed prices and higher insecticide and soybean seed volumes were offset by lower corn seed and herbicide volumes

2Q operating earnings 11% lower as higher seed prices and lower seed input costs were more than offset by lower overall volumes and higher seed inventory write-downs

1H sales were 4% lower as higher seed prices and higher crop protection volumes were more than offset by lower corn seed volumes. 1H operating earnings were 7% lower.

$100 million of operating earnings were realized in 4Q 2013 versus the 1Q due to earlier seed shipments


Appendix 1: Second Quarter 2014 Segment Commentary

17

This data should be read in conjunction with the Company’s second quarter earnings news release dated July 22, 2014 and DuPont’s 2Q 2014 Earnings Conference Call presentation materials and reconciliations of non-GAAP to GAAP measures included in the presentation materials and posted on the DuPont Investor Center website at www.dupont.com. Nutrition & Health Nutrition & Health, recorded a strong second quarter, building on momentum established in the third quarter of 2013. Sales were 7 percent higher, primarily due to broad based volume growth aided by improved product mix. We saw a strong recovery in Enablers and sustained momentum for probiotics and cultures. Volume grew in all regions and we continue to grow in emerging markets. Operating earnings of $105 million increased 72 percent from higher sales, lower raw material costs, productivity gains and the absence of one-time costs in the prior year. Operating margins for the quarter improved by over 400 basis points. This was the fourth consecutive quarter of year-over-year operating margin improvement. In the third quarter, we expect modest sales growth from continued broad based volume gains. Operating earnings are expected to be significantly higher due to increased sales, mix enrichment and continuing productivity actions. We will continue to make strategic investments in research, application development and customer facing resources to drive future growth. Operating margins are expected to continue the trend of year over year improvement.

Segment Commentary – Second Quarter Earnings 2014

18

Industrial Biosciences Industrial Biosciences sales of $317 million were 4 percent higher on higher prices due to mix enrichment, improved margins and higher volumes. Continued strong enzyme demand for ethanol production was partially offset by lower sales of Sorona® polymer due to lower existing home sales. Strong sales of Axtra® PHY in animal nutrition markets paired with healthy food enzyme demand also increased volumes and margins. Operating earnings of $59 million were up 37 percent, primarily driven by mix enrichment, improved margins associated with new products, and volumes in biorefineries and bioactives. For the first half, segment operating earnings were up 37% and operating margins are up 440 basis points from the prior year. Favorable industry fundamentals for ethanol are driving increased enzyme demand as ethanol margins are attractive and production is near capacity. Enzyme volumes in the grain ethanol market are also being driven by the roll out of DuPont’s Total Performance System (TPS) using novel enzymes and other functional bio-products designed to increase customer earnings through increased production rates, yield, and efficiency. Since introduction in late 2013, TPS has been adopted across a diverse set of ethanol production plants. Further adoptions are planned. We are implementing TPS as our standard offering for the industry, with next-generation versions already in preparation for launch. For the third quarter, we expect modest sales growth aided by continued enzyme demand for ethanol production and stronger forecasted sales of Sorona®. Third quarter operating earnings are expected to be up substantially driven primarily by higher volumes and improved margins.


19

Safety & Protection

Sales of $1,029 million were up 1 percent on higher volumes in industrial markets. Improved Nomex® thermal resistant and Kevlar® high strength materials demand was partially offset by lower sales from Clean Technologies offerings, as fewer sulfuric acid recovery plants were built.

Kevlar® demand growth was driven by increased sales into law enforcement, transportation and wire & cable sectors while Nomex demand improved in energy solution and thermal industrial applications. Regionally, sales volume growth was most notable in Europe and in Asia Pacific, partially offset by lower prices.

Second quarter segment operating earnings of $209 million increased 22 percent and operating margins increased over 300 basis points. Segment operating earnings are benefiting from improved margins, increased demand from industrial markets and continued benefits from cost productivity initiatives coupled with improved plant operating results.

For the third quarter, sales are anticipated to be up modestly reflecting improved industrial demand, and operating earnings will be up about 20 percent, driven by higher operating margins and sustained operational productivity.


20

Electronics & Communications Electronics & Communications sales were essentially flat excluding the impact of lower metals price pass through. Volume growth in most product lines, led by gains in consumer electronics, was offset by lower price due to metals, product mix and competitive pressures. Operating earnings declined $6 million as volume growth and productivity gains were more than offset by the absence of $20 million of OLED licensing income realized during the second quarter of 2013. Excluding the impact of last year’s licensing income, operating earnings increased 19 percent. Looking ahead to the third quarter, we continue to expect global photovoltaic module installations to be up for the year with mid-teens growth rates. We expect a strong 2H in photovoltaics driven by installations in China and good demand for our products in consumer electronics markets. Third quarter sales are expected to be slightly higher with operating earnings slightly lower due to a decrease in other income.


21

Performance Materials Sales of approximately $1.6 billion were down 2 percent principally due to the scheduled outage at the Orange, Texas ethylene unit and portfolio changes. Volumes in Performance Polymers were up mid-single digits fueled by strong automotive demand in China, Europe and North America. The demand environment in consumer, construction and food packaging markets remains stable. Demand for high performance parts, principally Kalrez® and Vespel® for electronics, oil and gas, and aerospace applications was up about 10 percent. Segment operating earnings were $303 million or 9 percent below last year as lower sales volume resulting from the scheduled ethylene outage was partially offset by sales gains in Performance Polymers. In the third quarter, we anticipate sales will be essentially flat versus the prior year as the impact of portfolio changes; principally the Glass Laminating/Vinyls sale in the second quarter offsets anticipated volume growth in Performance Polymers. We expect operating earnings will be up modestly from the prior year, which included a $30 million dollar benefit from a joint venture equity position.


22


Performance Chemicals Segment sales of approximately $1.7 billion were down 8 percent due to a portfolio change and lower prices. Slightly higher Ti02 volumes were more than offset by lower volumes in Chemicals and Fluoroproducts. Second quarter refrigerant prices for mobile and stationary applications were lower than expected as prices for R22 have not recovered from the prior year following the increase in production allocations granted by the U. S. Environmental Protection Agency. In addition, HFC prices, principally 134a, were under pressure due to heavy imports. Demand for Opteon® yf for mobile air conditioning continues to grow. In 2014, we anticipate sales will double to reach approximately $100 million as automotive OEMs increase their rate of adoption of this new product. In Ti02, volumes were up slightly from the prior year, marking six consecutive quarters of year over year volume growth. Ti02 prices were essentially flat sequentially but down about 3% on a year over year basis. We believe our customer’s inventory levels are stable and producer levels remain essentially unchanged. In the third quarter, we anticipate sales will be essentially flat and operating earnings up moderately on higher volumes and improved operating margins.

23


Agriculture In Agriculture, second quarter results finished in-line with the update we provided in late June. Supply-driven impacts on commodity prices led to reductions in corn planted area in the North America and Brazil Safrinha seasons. Second quarter sales were essentially flat as higher seed prices and higher insecticide and soybean seed volumes were offset by lower corn seed and herbicide volumes. Operating earnings for the quarter were 11 percent lower as higher seed prices and lower seed input costs were more than offset by lower overall volumes and higher seed inventory write-downs. For the first half, which encompasses the majority of the northern hemisphere season and the completion of Brazil’s Safrinha season, segment sales were 4 percent lower. Crop protection sales grew 4 percent in the first half driven by strong demand for insecticides in Latin America due to heavy insect pressure and the excellent performance of Rynaxypyr® insecticide. This was partially offset by lower herbicide volumes in North America and Europe. Herbicide volumes were negatively impacted by a wet spring, a delayed and compressed application season, and distributor de-stocking of elevated inventory levels. In seeds, first half sales were 6 percent lower. The first half comparison was negatively impacted by the earlier timing of seed shipments which caused about $100 million of operating earnings to be realized in the fourth quarter of 2013 rather than the first quarter this year. Higher prices and higher soybean volumes in North

(continued)

24


(continued) America were more than offset by the decline in corn seed volumes. Price gains were achieved in North America due to improved product mix as Optimum® AQUAmax® hybrids were planted on over 10 million acres and Optimum® AcreMax® products represented about two-thirds of our corn sales volume in North America. First half operating earnings for the segment were 7 percent lower as lower seed input costs were more than offset by lower sales and higher seed inventory write-downs. As we turn to the second half, we expect sales to be modestly higher with operating earnings substantially higher for the Agriculture segment. Rynaxypyr® is expected to continue to drive growth in insect control aided by new launches of Cyazypyr® and Lumigen™ seed treatments, including Dermacor™ for use on soybeans in Brazil. In seeds, we expect lower corn sales in Brazil’s summer season as growers continue to shift hectares from corn to soybeans. Corn seed price in Brazil is expected to be modestly lower reflecting the impact of fall armyworm resistance to the Herculex® 1 trait. Herculex® 1 combined with leading Pioneer germplasm continues to offer control of a broad spectrum of pests. We also expect early seed shipments for the 2015 Brazil Safrinha and northern hemisphere seasons to be similar to the prior year. While the cutoff between third quarter and fourth quarter sales comes at an important time in the Latin America season, we expect the third quarter to result in a similar loss as last year followed by a stronger fourth quarter. In addition, the third quarter comparison will be impacted by the absence of a $26 million equity re-measurement gain from the acquisition of Pannar which was recorded in the prior year.

Herculex® is a registered trademark of Dow AgroSciences LLC

Appendix 2: Supplemental Quarterly Information and Reconciliations of Non-GAAP Measures

INDEX PAGE

SELECTED OPERATING RESULTS 27

SELECTED INCOME STATEMENT DATA 28

SEGMENT SALES 29

SEGMENT PRETAX OPERATING INCOME 30

SEGMENT OPERATING EARNINGS 31

SIGNIFICANT ITEMS BY SEGMENT - PRETAX OPERATING INCOME 32

RECONCILIATION OF NON-GAAP MEASURES 33-35

Note: Management believes that an analysis of operating earnings (as defined on page 27), a "non-GAAP" measure, is meaningful to investors because it provides insight with respect to ongoing operating results of the company. Such measurements are not recognized in accordance with generally accepted accounting principles (GAAP) and should not be viewed as an alternative to GAAP measures of performance.

E. I. DU PONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIESQUARTERLY SUPPLEMENTAL FINANCIAL DATA AND NON-GAAP RECONCILIATIONS

(UNAUDITED)JUNE 30, 2014

2Q14 Supplemental Financial Data and Non-GAAP Reconciliations 7/22/2014

E. I. DU PONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES

Year Year Year Year2014 2Q14 1Q14 2013 4Q13 3Q13 2Q13 1Q13 2012 4Q12 3Q12 2Q12 1Q12 2011 4Q11 3Q11 2Q11 1Q11

INCOME STATEMENT DATAConsolidated Net Sales 19,834 9,706 10,128 35,734 7,747 7,735 9,844 10,408 34,812 7,325 7,390 9,917 10,180 33,681 7,343 8,138 9,159 9,041

Operating Earnings After Income Taxes (1) 2,557 1,085 1,472 3,632 558 426 1,189 1,459 3,566 193 405 1,421 1,547 3,790 346 684 1,318 1,442

Significant Items - After-tax (4) 8 (12) (423) (294) (71) (78) 20 (680) (91) (342) (215) (32) (237) 47 (203) (81) -

Non-Operating Pension & OPEB Costs - After-tax (44) (23) (21) (360) (81) (95) (85) (99) (439) (99) (106) (116) (118) (361) (90) (91) (90) (90)

Income from Continuing Operations After Income TaxesAttributable to DuPont 2,509 1,070 1,439 2,849 183 260 1,026 1,380 2,447 3 (43) 1,090 1,397 3,192 303 390 1,147 1,352

Depreciation 635 323 312 1,280 319 317 317 327 1,319 328 331 332 328 1,199 318 316 292 273

STATEMENT OF CASH FLOW DATA (2)Cash Provided by (Used for) Operating Activities (2,071) 350 (2,421) 3,179 5,512 298 36 (2,667) 4,849 5,275 691 760 (1,877) 5,152 4,721 1,075 840 (1,484)

Capital Expenditures (3) 804 462 342 1,940 674 478 449 339 1,890 720 460 407 303 1,910 664 478 433 335

(1) Operating earnings are defined as earnings from continuing operations (GAAP) excluding “significant items” and “non-operating pension and other post-employment benefit (OPEB) costs”.(2) Data is on a total company basis.(3) Includes purchases of property, plant and equipment and investment in affiliates.

Note: The data above provides a historical display of Selected Income Statement Data included in our Quarterly EarningsRelease financials. See Quarterly Earnings Release financials for full details, including details on "Significant Items".

SELECTED OPERATING RESULTS (UNAUDITED)(dollars in millions)

2Q14 Supplemental Financial Data and Non-GAAP Reconciliations 27 7/22/2014



Consolidated Net Sales 19,834 9,706 10,128 35,734 7,747 7,735 9,844 10,408 34,812 7,325 7,390 9,917 10,180 33,681 7,343 8,138 9,159 9,041

Segment Sales 19,992 9,783 10,209 36,046 7,814 7,813 9,925 10,494 35,194 7,397 7,480 10,022 10,295 34,087 7,444 8,236 9,263 9,144

Segment Operating Earnings (1) 4,018 1,770 2,248 5,925 939 853 1,857 2,276 6,251 616 921 2,241 2,473 6,292 820 1,215 2,074 2,183

Adjusted EBIT (Operating Earnings) (1) (2) 3,474 1,529 1,945 5,021 675 587 1,693 2,066 5,147 346 614 2,058 2,129 5,293 637 1,019 1,826 1,811

Adjusted EBITDA (Operating Earnings) (1) (2) 4,354 1,972 2,382 6,624 1,062 966 2,097 2,499 6,778 740 1,007 2,475 2,556 6,744 1,030 1,386 2,182 2,146

Operating Earnings Before Income Taxes (1) 3,287 1,439 1,848 4,587 567 482 1,582 1,956 4,708 230 501 1,950 2,027 4,886 524 914 1,724 1,724

Operating Earnings Per Share (1) (3) 2.75 1.17 1.58 3.88 0.59 0.45 1.28 1.56 3.77 0.20 0.43 1.50 1.64 4.02 0.37 0.72 1.39 1.53

(1) See Reconciliation of Non-GAAP Measures.

(2) Adjusted EBIT from operating earnings is operating earnings (as defined on page 27) before income taxes, net income attributable to noncontrolling interests and interest expense. Adjusted EBITDA from operating earnings is adjusted EBIT from operating earnings before depreciation and amortization of intangible assets.

(3) Earnings per share for the year may not equal the sum of quarterly earnings per share due to changes in average share calculations.

Note:

SELECTED INCOME STATEMENT DATAOPERATING EARNINGS (UNAUDITED)(dollars in millions, except per share)

The data above provides a historical display of Selected Income Statement Data included in our Quarterly Earnings Release financials. See Quarterly Earnings Release financials for full details, including details on "Significant Items".




Agriculture 8,009 3,615 4,394 11,739 1,806 1,633 3,631 4,669 10,426 1,535 1,423 3,388 4,080 9,166 1,297 1,368 2,997 3,504 Electronics & Communications 1,197 617 580 2,549 642 638 653 616 2,701 622 607 795 677 3,173 630 841 891 811 Industrial Biosciences 618 317 301 1,224 326 305 304 289 1,180 300 292 300 288 705 289 293 123 - Nutrition & Health 1,787 926 861 3,473 872 868 865 868 3,422 853 876 885 808 2,460 806 844 486 324 Performance Chemicals(1) 3,287 1,696 1,591 6,932 1,671 1,781 1,837 1,643 7,450 1,644 1,794 2,043 1,969 8,055 1,923 2,209 2,065 1,858 Performance Materials(1) 3,116 1,582 1,534 6,239 1,521 1,602 1,615 1,501 6,185 1,478 1,552 1,624 1,531 6,554 1,555 1,678 1,675 1,646 Safety & Protection 1,976 1,029 947 3,884 975 985 1,017 907 3,825 964 934 986 941 3,934 943 1,001 1,025 965 Other 2 1 1 6 1 1 3 1 5 1 2 1 1 40 1 2 1 36

Total Segment Sales 19,992 9,783 10,209 36,046 7,814 7,813 9,925 10,494 35,194 7,397 7,480 10,022 10,295 34,087 7,444 8,236 9,263 9,144

Elimination of Transfers (158) (77) (81) (312) (67) (78) (81) (86) (382) (72) (90) (105) (115) (406) (101) (98) (104) (103)

CONSOLIDATED NET SALES 19,834 9,706 10,128 35,734 7,747 7,735 9,844 10,408 34,812 7,325 7,390 9,917 10,180 33,681 7,343 8,138 9,159 9,041

(1) Prior periods reflect the reclassifications of Viton® fluoroelastomers from Performance Materials to Performance Chemicals.

Note: The data above provides a historical display of selected data included in our Quarterly Earnings Release financials.

SEGMENT SALES

SEGMENT SALES (UNAUDITED)(dollars in millions)




Agriculture 2,231 789 1,442 2,132 (108) (102) 861 1,481 1,669 (103) (198) 682 1,288 1,566 (222) (184) 843 1,129 Electronics & Communications 96 21 75 203 (38) 97 95 49 222 41 (99) 221 59 438 61 120 126 131 Industrial Biosciences 113 57 56 170 41 45 43 41 159 41 37 42 39 2 34 (26) (6) - Nutrition & Health 190 97 93 305 87 81 61 76 270 22 64 105 79 76 54 (20) 14 28 Performance Chemicals(1) 438 232 206 941 228 189 268 256 1,826 210 417 613 586 2,162 496 651 571 444 Performance Materials(1) 958 665 293 1,264 278 367 332 287 1,073 263 223 325 262 1,031 209 251 270 301 Safety & Protection 353 178 175 694 213 171 172 138 562 130 92 181 159 661 131 162 184 184 Other (176) (84) (92) (340) (91) (107) (55) (87) (412) (80) (75) (208) (49) (55) (11) (32) 22 (34)

TOTAL SEGMENT PRETAX OPERATING INCOME 4,203 1,955 2,248 5,369 610 741 1,777 2,241 5,369 524 461 1,961 2,423 5,881 752 922 2,024 2,183

Net Exchange (Losses) Gains (205) (109) (96) (128) (73) (101) 35 11 (215) (54) (130) 50 (81) (146) (14) 6 3 (141) Non-Operating Pension & OPEBs Costs (64) (34) (30) (539) (124) (142) (126) (147) (654) (147) (157) (174) (176) (540) (135) (135) (135) (135) Corporate Expenses (495) (278) (217) (765) (183) (162) (206) (214) (948) (240) (233) (224) (251) (869) (166) (194) (291) (218) Interest Expense (197) (94) (103) (448) (108) (108) (115) (117) (464) (117) (116) (117) (114) (447) (116) (116) (115) (100)

INCOME (LOSS) FROM CONTINUING OPERATIONSBEFORE INCOME TAXES 3,242 1,440 1,802 3,489 122 228 1,365 1,774 3,088 (34) (175) 1,496 1,801 3,879 321 483 1,486 1,589

(723) (366) (357) (626) 61 35 (335) (387) (616) 38 135 (397) (392) (647) (15) (82) (326) (224)

INCOME (LOSS) FROM CONTINUING OPERATIONSAFTER INCOME TAXES 2,519 1,074 1,445 2,863 183 263 1,030 1,387 2,472 4 (40) 1,099 1,409 3,232 306 401 1,160 1,365



SEGMENT PRETAX OPERATING INCOME (LOSS)

INCOME FROM CONTINUING OPERATIONS (UNAUDITED)(dollars in millions)

(Provision For) Benefit From Income Taxes on Continuing Operations




Agriculture 2,278 836 1,442 2,483 88 (62) 941 1,516 2,138 (77) (70) 947 1,338 1,791 (122) (59) 843 1,129 Electronics & Communications 164 89 75 334 93 97 95 49 259 43 58 99 59 438 61 120 126 131 Industrial Biosciences 115 59 56 169 40 45 43 41 162 41 40 42 39 81 35 35 11 - Nutrition & Health 198 105 93 299 81 81 61 76 319 58 77 105 79 202 58 69 47 28 Performance Chemicals(1) 457 251 206 1,015 230 261 268 256 1,862 243 420 613 586 2,162 496 651 571 444 Performance Materials(1) 596 303 293 1,280 294 367 332 287 1,177 266 324 325 262 984 162 251 270 301 Safety & Protection 384 209 175 690 209 171 172 138 620 133 147 181 159 661 131 162 184 184 Other (174) (82) (92) (345) (96) (107) (55) (87) (286) (91) (75) (71) (49) (27) (1) (14) 22 (34)

TOTAL SEGMENT OPERATING EARNINGS 4,018 1,770 2,248 5,925 939 853 1,857 2,276 6,251 616 921 2,241 2,473 6,292 820 1,215 2,074 2,183

Corporate Expenses (387) (186) (201) (762) (191) (162) (195) (214) (864) (215) (174) (224) (251) (813) (166) (191) (238) (218) Interest Expense (197) (94) (103) (448) (108) (108) (115) (117) (464) (117) (116) (117) (114) (447) (116) (116) (115) (100)

3,434 1,490 1,944 4,715 640 583 1,547 1,945 4,923 284 631 1,900 2,108 5,032 538 908 1,721 1,865

(745) (347) (398) (983) (43) (111) (373) (456) (1,190) (61) (164) (460) (505) (1,137) (155) (177) (401) (404) Net After-tax Exhange (Losses) Gains (122) (54) (68) (86) (39) (43) 19 (23) (142) (29) (59) (10) (44) (65) (34) (36) 11 (6) Less: Net Income Attr. to Noncontrolling Interests 10 4 6 14 - 3 4 7 25 1 3 9 12 40 3 11 13 13

OPERATING EARNINGS 2,557 1,085 1,472 3,632 558 426 1,189 1,459 3,566 193 405 1,421 1,547 3,790 346 684 1,318 1,442

Net Income Attributable to Noncontrolling Interests 10 4 6 14 - 3 4 7 25 1 3 9 12 40 3 11 13 13 Non-Operating Pension & OPEB Costs - After-tax (44) (23) (21) (360) (81) (95) (85) (99) (439) (99) (106) (116) (118) (361) (90) (91) (90) (90) Significant Items - After-tax (4) 8 (12) (423) (294) (71) (78) 20 (680) (91) (342) (215) (32) (237) 47 (203) (81) -

INCOME (LOSS) FROM CONTINUING OPERATIONSAFTER INCOME TAXES 2,519 1,074 1,445 2,863 183 263 1,030 1,387 2,472 4 (40) 1,099 1,409 3,232 306 401 1,160 1,365



OPERATING EARNINGS BEFORE INCOME TAXES AND EXCHANGE (LOSSES) GAINS

Provision For Income Taxes on Operating Earnings, Excluding Taxes on Exchange Gains (Losses)

SEGMENT OPERATING EARNINGS

OPERATING EARNINGS (UNAUDITED) (dollars in millions)



SEGMENT PRETAX IMPACT OF Year Year Year YearSIGNIFICANT ITEMS 2014 2Q14 1Q14 2013 4Q13 3Q13 2Q13 1Q13 2012 4Q12 3Q12 2Q12 1Q12 2011 4Q11 3Q11 2Q11 1Q11

Agriculture (47) (47) - (351) (196) (40) (80) (35) (469) (26) (128) (265) (50) (225) (100) (125) - - Electronics & Communications (68) (68) - (131) (131) - - - (37) (2) (157) 122 - - - - - - Industrial Biosciences (2) (2) - 1 1 - - - (3) - (3) - - (79) (1) (61) (17) - Nutrition & Health (8) (8) - 6 6 - - - (49) (36) (13) - - (126) (4) (89) (33) - Performance Chemicals (19) (19) - (74) (2) (72) - - (36) (33) (3) - - - - - - - Performance Materials 362 362 - (16) (16) - - - (104) (3) (101) - - 47 47 - - - Safety & Protection (31) (31) - 4 4 - - - (58) (3) (55) - - - - - - - Other (2) (2) - 5 5 - - - (126) 11 - (137) - (28) (10) (18) - -

TOTAL SIGNIFICANT ITEMS BY SEGMENT - PRETAX 185 185 - (556) (329) (112) (80) (35) (882) (92) (460) (280) (50) (411) (68) (293) (50) -

Note: The data above provides a historical display of significant items included in our Quarterly Earnings Release financials.

SIGNIFICANT ITEMS BY SEGMENT - PRETAX OPERATING INCOME (UNAUDITED)(dollars in millions)




RECONCILIATION OF DILUTED EPS (1)

Operating EPS 2.75 1.17 1.58 3.88 0.59 0.45 1.28 1.56 3.77 0.20 0.43 1.50 1.64 4.02 0.37 0.72 1.39 1.53 Non-Operating Pension & OPEB Costs (0.05) (0.03) (0.03) (0.39) (0.09) (0.09) (0.10) (0.11) (0.46) (0.11) (0.11) (0.12) (0.12) (0.39) (0.10) (0.10) (0.10) (0.10) Significant Items - 0.01 (0.01) (0.45) (0.31) (0.08) (0.08) 0.02 (0.72) (0.09) (0.37) (0.23) (0.04) (0.25) 0.05 (0.21) (0.08) - GAAP EPS from continuing operations 2.70 1.15 1.54 3.04 0.19 0.28 1.10 1.47 2.59 - (0.05) 1.15 1.48 3.38 0.32 0.41 1.21 1.43

RECONCILIATION OF SEGMENT PTOI

Segment Operating Earnings 4,018 1,770 2,248 5,925 939 853 1,857 2,276 6,251 616 921 2,241 2,473 6,292 820 1,215 2,074 2,183 Significant Items included in Segment PTOI 185 185 - (556) (329) (112) (80) (35) (882) (92) (460) (280) (50) (411) (68) (293) (50) - Segment PTOI 4,203 1,955 2,248 5,369 610 741 1,777 2,241 5,369 524 461 1,961 2,423 5,881 752 922 2,024 2,183

RECONCILIATION OF ADJUSTED EBIT / ADJUSTED EBITDA TO CONSOLIDATED INCOME STATEMENTS

Income From Continuing Operations Before Income Taxes 3,242 1,440 1,802 3,489 122 228 1,365 1,774 3,088 (34) (175) 1,496 1,801 3,879 321 483 1,486 1,589 Add: Significant Items - Pretax - (Benefit) / Charge (19) (35) 16 559 321 112 91 35 966 117 519 280 50 467 68 296 103 - Add: Non-Operating Pension & OPEB Costs - Pretax 64 34 30 539 124 142 126 147 654 147 157 174 176 540 135 135 135 135 Operating Earnings Before Income Taxes 3,287 1,439 1,848 4,587 567 482 1,582 1,956 4,708 230 501 1,950 2,027 4,886 524 914 1,724 1,724 Less: Net Income Attributable to Noncontrolling Interests 10 4 6 14 - 3 4 7 25 1 3 9 12 40 3 11 13 13 Add: Interest Expense 197 94 103 448 108 108 115 117 464 117 116 117 114 447 116 116 115 100

Adjusted EBIT (Operating Earnings) 3,474 1,529 1,945 5,021 675 587 1,693 2,066 5,147 346 614 2,058 2,129 5,293 637 1,019 1,826 1,811

Add: Depreciation and Amortization 880 443 437 1,603 387 379 404 433 1,631 394 393 417 427 1,451 393 367 356 335

Adjusted EBITDA (Operating Earnings) 4,354 1,972 2,382 6,624 1,062 966 2,097 2,499 6,778 740 1,007 2,475 2,556 6,744 1,030 1,386 2,182 2,146

(1) Earnings per share for the year may not equal the sum of quarterly earnings per share due to changes in average share calculations.

RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED)(dollars in millions, except per share)



Jun-14 Mar-14 Dec-13 Sep-13 Jun-13 Mar-13 Dec-12 Sep-12 Jun-12 Mar-12 Dec-11 Sep-11 Jun-11 Mar-11CALCULATION OF NET DEBT

Cash and Cash Equivalents 4,174 3,782 8,941 7,005 6,685 6,555 4,284 3,418 3,506 3,410 3,586 2,750 2,268 3,796 Marketable Securities 173 67 145 184 211 26 123 105 50 191 433 229 214 1,026 Total Cash 4,347 3,849 9,086 7,189 6,896 6,581 4,407 3,523 3,556 3,601 4,019 2,979 2,482 4,822

Short-Term Borrowings and Capital Lease Obligations 2,506 2,019 1,721 4,204 3,315 2,006 1,275 4,564 3,696 3,593 817 3,301 2,336 2,137 Long-Term Borrowings and Capital Lease Obligations 9,292 9,298 10,741 10,755 10,765 11,279 10,465 10,502 11,254 11,232 11,736 12,200 12,460 10,114 Total Debt 11,798 11,317 12,462 14,959 14,080 13,285 11,740 15,066 14,950 14,825 12,553 15,501 14,796 12,251

Debt (Net of all Cash) 7,451 7,468 3,376 7,770 7,184 6,704 7,333 11,543 11,394 11,224 8,534 12,522 12,314 7,429


CALCULATION OF FREE CASH FLOW

Cash (Used for) Provided by Operating Activities (2,071) 350 (2,421) 3,179 5,512 298 36 (2,667) 4,849 5,275 691 760 (1,877) 5,152 4,721 1,075 840 (1,484) Less: Purchases of Property, Plant and Equipment 781 461 320 1,882 659 466 436 321 1,793 654 443 395 301 1,843 632 470 418 323 Free Cash Flow (2,852) (111) (2,741) 1,297 4,853 (168) (400) (2,988) 3,056 4,621 248 365 (2,178) 3,309 4,089 605 422 (1,807)

RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED)(dollars in millions)




SEGMENT PTOI MARGIN % (PTOI / Segment Sales) (1)

Agriculture 27.9% 21.8% 32.8% 18.2% -6.0% -6.2% 23.7% 31.7% 16.0% -6.7% -13.9% 20.1% 31.6% 17.1% -17.1% -13.5% 28.1% 32.2%Electronics & Communications 8.0% 3.4% 12.9% 8.0% -5.9% 15.2% 14.5% 8.0% 8.2% 6.6% -16.3% 27.8% 8.7% 13.8% 9.7% 14.3% 14.1% 16.2%Industrial Biosciences 18.3% 18.0% 18.6% 13.9% 12.6% 14.8% 14.1% 14.2% 13.5% 13.7% 12.7% 14.0% 13.5% 0.3% 11.8% -8.9% -4.9% n/mNutrition & Health 10.6% 10.5% 10.8% 8.8% 10.0% 9.3% 7.1% 8.8% 7.9% 2.6% 7.3% 11.9% 9.8% 3.1% 6.7% -2.4% 2.9% 8.6%Performance Chemicals(2) 13.3% 13.7% 12.9% 13.6% 13.6% 10.6% 14.6% 15.6% 24.5% 12.8% 23.2% 30.0% 29.8% 26.8% 25.8% 29.5% 27.7% 23.9%Performance Materials(2) 30.7% 42.0% 19.1% 20.3% 18.3% 22.9% 20.6% 19.1% 17.3% 17.8% 14.4% 20.0% 17.1% 15.7% 13.4% 15.0% 16.1% 18.3%Safety & Protection 17.9% 17.3% 18.5% 17.9% 21.8% 17.4% 16.9% 15.2% 14.7% 13.5% 9.9% 18.4% 16.9% 16.8% 13.9% 16.2% 18.0% 19.1%

TOTAL SEGMENT PTOI MARGIN % 21.0% 20.0% 22.0% 14.9% 7.8% 9.5% 17.9% 21.4% 15.3% 7.1% 6.2% 19.6% 23.5% 17.3% 10.1% 11.2% 21.9% 23.9%

SEGMENT OPERATING EARNINGS MARGIN % (Operating Earnings / Segment Sales) (1)

Agriculture 28.4% 23.1% 32.8% 21.2% 4.9% -3.8% 25.9% 32.5% 20.5% -5.0% -4.9% 28.0% 32.8% 19.5% -9.4% -4.3% 28.1% 32.2%Electronics & Communications 13.7% 14.4% 12.9% 13.1% 14.5% 15.2% 14.5% 8.0% 9.6% 6.9% 9.6% 12.5% 8.7% 13.8% 9.7% 14.3% 14.1% 16.2%Industrial Biosciences 18.6% 18.6% 18.6% 13.8% 12.3% 14.8% 14.1% 14.2% 13.7% 13.7% 13.7% 14.0% 13.5% 11.5% 12.1% 11.9% 8.9% n/mNutrition & Health 11.1% 11.3% 10.8% 8.6% 9.3% 9.3% 7.1% 8.8% 9.3% 6.8% 8.8% 11.9% 9.8% 8.2% 7.2% 8.2% 9.7% 8.6%Performance Chemicals(2) 13.9% 14.8% 12.9% 14.6% 13.8% 14.7% 14.6% 15.6% 25.0% 14.8% 23.4% 30.0% 29.8% 26.8% 25.8% 29.5% 27.7% 23.9%Performance Materials(2) 19.1% 19.2% 19.1% 20.5% 19.3% 22.9% 20.6% 19.1% 19.0% 18.0% 20.9% 20.0% 17.1% 15.0% 10.4% 15.0% 16.1% 18.3%Safety & Protection 19.4% 20.3% 18.5% 17.8% 21.4% 17.4% 16.9% 15.2% 16.2% 13.8% 15.7% 18.4% 16.9% 16.8% 13.9% 16.2% 18.0% 19.1%

20.1% 18.1% 22.0% 16.4% 12.0% 10.9% 18.7% 21.7% 17.8% 8.3% 12.3% 22.4% 24.0% 18.5% 11.0% 14.8% 22.4% 23.9%

(1) Segment PTOI / Operating Earnings margin %'s for Other are not presented separately above as they are not meaningful; however, the results are included in the Total margin %'s above.


TOTAL SEGMENT OPERATING EARNINGS MARGIN %

RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED)



2014 2013 2014 2013 2014 Outlook1

2013 Actual

Effective income tax rate 25.4% 24.5% 22.3% 23.0% 22.1% 17.9%

Significant items effect and non-operating pension/OPEB costs effect (1.1%) 0.1% (0.4%) 1.8% 0.1% 2.6%

24.3% 24.6% 21.9% 24.8% 22.2% 20.5%

Exchange gains (losses) effect2

(1.0%) (0.5%) (0.2%) (1.1%) (0.2%) 0.3%

Base income tax rate from continuing operations 23.3% 24.1% 21.7% 23.7% 22.0% 20.8%

1 - Represents the company's anticipated full year tax rates.

2 - For the 2014 outlook, the effect of exchange gains (losses) on the company’s full year effective income tax rate reflects actual exchange gains (losses) from the six

months ended June 30, 2014 only.

Tax rate, from continuing operations, before significant items and

non-operating pension/OPEB costs

RECONCILIATION OF BASE INCOME TAX RATE TO EFFECTIVE INCOME TAX RATE (UNAUDITED)

Base income tax rate is defined as the effective income tax rate less the effect of exchange gains (losses), significant items and non-operating pension/OPEB

costs.

Three months ended

June 30, Year ended December 31,

Six months ended

June 30,

leg171

Typewritten Text

leg171

Typewritten Text

36

leg171

Typewritten Text

leg171

Typewritten Text

leg171

Typewritten Text

leg171

Typewritten Text

leg171

Typewritten Text

leg171

Typewritten Text

leg171

Typewritten Text

leg171

Typewritten Text

leg171

Typewritten Text

leg171

Typewritten Text

leg171

Typewritten Text

26

Copyright © 2014 DuPont. All rights reserved. The DuPont Oval Logo, DuPontTM, The miracles of scienceTM, and, unless otherwise indicated, all products denoted with ® or M are trademarks or registered trademarks of E. I. du Pont de Nemours and Company.

Investor Relations

2 q14 slides final